TP53 and hepatocellular carcinoma: Yang et al. compared rAd-p53 combined with fractionated stereotactic radiotherapy (fSRT) for HCC with fSRT alone (fSRT group) or rAd-p53 combined with fSRT (combined group), and the results showed that the combined group was a relatively safe and effective method to treat HCC [53].